Delivery of therapeutic capable agents

• US 20030050692A1
• Filed: 07/25/2002
• Published: 03/13/2003
• Est. Priority Date: 12/22/2000
• Status: Abandoned Application

• Current Assignee: Avantec Vascular Corporation
• Original Assignee: Avantec Vascular Corporation
• Inventors: Yan, John, Sirhan, Motasim
• Application Number:
  US10/206,807
• Publication Number:
  US 20030050692A1
• Time in Patent Office: Days
• US Class Current: 623/1.42
• CPC Class Codes: A61F 2/91 made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
• CPC Class Codes: A61F 2/915 with bands having a meander structure, adjacent bands being connected to each other
• CPC Class Codes: A61F 2/95 Instruments specially adapted for placement or removal of stents or stent-grafts
• CPC Class Codes: A61F 2002/91533 characterised by the phase between adjacent bands
• CPC Class Codes: A61F 2002/91558 connected peak to peak
• CPC Class Codes: A61F 2230/0054 V-shaped
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61F 2250/0068 the pharmaceutical product being in a reservoir
• CPC Class Codes: A61F 2250/0071 breakable or frangible
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

Devices and methods for reducing, inhibiting, or treating restenosis and hyperplasia after intravascular intervention are provided. In particular, the present invention provides luminal prostheses which allow for controlled release of at least one therapeutic capable agent with increased efficacy to selected locations within a patient'"'"'s vasculature to reduce restenosis. An intraluminal prosthesis may comprise an expandable structure and a source adjacent the expandable structure for releasing the therapeutic capable agent into a body lumen to reduce smooth muscle cell proliferation.

Claims

1. A method for treatment of a patient, the method comprising:

providing a vascular prosthesis comprising a structure and at least one source of at least one therapeutic capable agent associated with the structure;

implanting the vascular prosthesis within the patient'"'"'s vasculature including a susceptible tissue site;

releasing the at least one therapeutic capable agent.

2. The method of claim 1, wherein releasing comprises releasing at least one therapeutic capable agent selected from the group consisting of immunosuppressants, anti-inflammatories, anti-proliferatives, anti-migratory agents, anti-fibrotic agents, proapoptotics, vasodilators, calcium channel blockers, anti-neoplastics, anti-cancer agents, antibodies, anti-thrombotic agents, anti-platelet agents, IIb/IIIa agents, antiviral agents, mTOR (mammalian target of rapamycin) inhibitors, non-immunosuppressant agents, and combinations thereof.

3. The method of claim 1, wherein releasing comprises releasing at least one therapeutic capable agent selected from the group consisting of mycophenolic acid, mycophenolic acid derivatives (e.g., 2-methoxymethyl derivative and 2-methyl derivative), VX-148, VX-944, mycophenolate mofetil, mizoribine, methylprednisolone, dexamethasone, CERTICAN™

(e.g., everolimus, RAD), rapamycin, ABT-773 (Abbot Labs), ABT-797 (Abbot Labs), TRIPTOLIDE™

, METHOTREXATE™

, phenylalkylamines (e.g., verapamil), benzothiazepines (e.g., diltiazem), 1,4-dihydropyridines (e.g., benidipine, nifedipine, nicarrdipine, isradipine, felodipine, amlodipine, nilvadipine, nisoldipine, manidipine, nitrendipine, barnidipine (HYPOCA™

)), ASCOMYCIN™

, WORTMANNIN™

, LY294002, CAMPTOTHECIN™

, flavopiridol, isoquinoline, HA-1077 (1-(5-isoquinolinesulfonyl)-homopiperazine hydrochloride), TAS-301 (3-bis(4-methoxyphenyl)methylene-2-indolinone), TOPOTECAN™

, hydroxyurea, TACROLIMUS™

(FK

     506), cyclophosphamide, cyclosporine, daclizumab, azathioprine, prednisone, diferuloymethane, diferuloylmethane, diferulylmethane, GEMCITABINE™

, cilostazol (PLETAL™

), tranilast, enalapril, quercetin, suramin, estradiol, cycloheximide, tiazofurin, zafurin, AP23573, rapamycin derivatives, non-immunosuppressive analogues of rapamycin (e.g., rapalog, AP21967, derivatives of rapalog), CCI-779 (an analogue of rapamcin available from Wyeth), sodium mycophenolic acid, benidipine hydrochloride, sirolimus, rapamune, metabolites, derivatives, and combinations thereof.

4. The method of claim 1, wherein the at least one therapeutic capable agent includes an active compound, a pro-drug of the active compound, a metabolite of the active compound, a derivative of the active compound, an analogue of the active compound, or a combination thereof.

5. The method of claim 1, wherein the at least one therapeutic capable agent is released within a time period from about the first day to about 200^th day from the implanting of the prosthesis.

6. The method of claim 1, wherein the at least one therapeutic capable agent is released at a total amount ranging from about 0.1 μ

g to about 10 g.

7. The method of claim 1, wherein the at least one therapeutic capable agent is released at a rate between about 0.001 μ

g/day to about 500 μ

g/day.

8. The method of claim 1, wherein the structure has a luminal facing surface and a tissue facing surface.

9. The method of claim 8, wherein the at least one therapeutic capable agent is associated with the structure only at one of the luminal and tissue facing surfaces.

10. The method of claim 8, wherein the at least one therapeutic capable agent is associated with the structure at the tissue facing surface.

11. The method of claim 8, wherein the at least one therapeutic capable agent is associated with the structure at both luminal and tissue facing surfaces.

12. The method of claim 1, wherein releasing comprises releasing the at least one therapeutic capable agent to the susceptible tissue site to effectuate a mammalian tissue concentration ranging from about 0.15 ng of therapeutic capable agent/mg of tissue to about 3 ng of therapeutic capable agent/mg of tissue.

13. The method of claim 4 or 12, wherein the therapeutic capable agent comprises mycophenolic acid.

14. The method of claim 1, wherein releasing comprises releasing the at least one therapeutic capable agent to the susceptible tissue site to effectuate an unwanted metabolite of the therapeutic capable agent having a mammalian tissue concentration of less than 2.5 ng/mg of tissue.

15. The method of claim 1, wherein releasing comprises releasing the at least one therapeutic capable agent to the susceptible tissue site to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 1.1 ng/mg of tissue.

16. The method of claim 1, wherein releasing comprises releasing the at least one therapeutic capable agent to the susceptible tissue site to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 0.5 ng/mg of tissue.

17. The method of claim 1, wherein releasing comprises releasing the at least one therapeutic capable agent to the susceptible tissue site to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 0.25 ng/mg of tissue.

18. The method of claim 1, wherein releasing comprises releasing the at least one therapeutic capable agent to the susceptible tissue site to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 0.10 ng/mg of tissue.

19. The method of claim 1, wherein releasing comprises releasing the at least one therapeutic capable agent to the susceptible tissue site to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of substantially zero.

20. A device for intracorporeal use, the device comprising:

an expandable structure; and

at least one source of at least one therapeutic capable agent associated with the structure.

21. The device of claim 20, wherein the expandable structure has a luminal facing surface and a tissue facing surface.

22. The device of claim 21, wherein the at least one therapeutic capable agent is associated with the expandable structure only on one of the luminal and tissue facing surfaces.

23. The device of claim 21, wherein the at least one therapeutic capable agent is associated with the expandable structure on the tissue facing surface.

24. The device of claim 21, wherein the at least one therapeutic capable agent is associated with the expandable structure on both luminal and tissue facing surfaces.

25. The device of claim 21, wherein the at least one source is disposed adjacent at least one of the luminal or tissue facing surfaces of the expandable structure.

26. The device of claim 21, wherein the at least one source is a reservoir disposed adjacent the expandable structure.

27. The device of claim 26, wherein the reservoir is at least partially on either or both the luminal and the tissue facing surfaces of the expandable structure.

28. The device of claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent at a phase to a susceptible tissue site of a mammalian intracorporeal body to effectuate a mammalian tissue concentration ranging from about 0.001 ng of therapeutic capable agent/mg of tissue to about 100 μ

g of therapeutic capable agent/mg of tissue.

29. The device of claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent to a susceptible tissue site of a mammalian intracorporeal body to effectuate a mammalian tissue concentration ranging from about 0.15 ng of therapeutic capable agent/mg of tissue to about 3 ng of therapeutic capable agent/mg of tissue.

30. The device of claim 20 or 29, wherein the therapeutic capable agent is mycophenolic acid.

31. The device of claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent to a susceptible tissue site of a mammalian intracorporeal body to effectuate an unwanted metabolite of the therapeutic capable agent having a mammalian tissue concentration of less than 2.5 ng/mg of tissue.

32. The device of claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent to a susceptible tissue site of a mammalian intracorporeal body to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 1.1 ng/mg of tissue.

33. The device of claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent to a susceptible tissue site of a mammalian intracorporeal body to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 0.5 ng/mg of tissue.

34. The device of claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent to a susceptible tissue site of a mammalian intracorporeal body to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 0.25 ng/mg of tissue.

35. The device of claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent to a susceptible tissue site of a mammalian intracorporeal body to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 0.10 ng/mg of tissue.

36. The device of claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent to a susceptible tissue site of a mammalian intracorporeal body to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of substantially zero.

37. The device of claim 20, wherein the at least one therapeutic capable agent is selected from the group consisting of immunosuppressants, anti-inflammatories, anti-proliferatives, anti-migratory agents, anti-fibrotic agents, proapoptotics, vasodilators, calcium channel blockers, anti-neoplastics, anti-cancer agents, antibodies, anti-thrombotic agents, anti-platelet agents, IIb/IIIa agents, antiviral agents, mTOR (mammalian target of rapamycin) inhibitors, non-immunosuppressant agents, and a combination thereof.

38. The device of claim 20, wherein the at least one therapeutic capable agent is selected from the group consisting of mycophenolic acid, mycophenolic acid derivatives (e,.g., 2-methoxymethyl derivative and 2-methyl derivative), VX-148, VX-944, mycophenolate mofetil, mizoribine, methylprednisolone, dexamethasone, CERTICAN ™

(e.g., everolimus, RAD), rapamycin, ABT-773 (Abbot Labs), ABT-797 (Abbot Labs), TRIPTOLIDE™

, METHOTREXATE™

, phenylalkylamines (e.g., verapamil), benzothiazepines (e.g., diltiazem), 1,4-dihydropyridines (e.g., benidipine, nifedipine, nicarrdipine, isradipine, felodipine, amlodipine, nilvadipine, nisoldipine, manidipine, nitrendipine, barnidipine (HYPOCA™

)), ASCOMYCIN™

, WORTMANNIN™

, LY294002, CAMPTOTHECIN™

, flavopiridol, isoquinoline, HA-1077 (1-(5-isoquinolinesulfonyl)-homopiperazine hydrochloride), TAS-301 (3-bis(4-methoxyphenyl)methylene-2-indolinone), TOPOTECAN™

, hydroxyurea, TACROLIMUS™

(FK

     506), cyclophosphamide, cyclosporine, daclizumab, azathioprine, prednisone, diferuloymethane, diferuloylmethane, diferulylmethane, GEMCITABINE™

, cilostazol (PLETAL™

), tranilast, enalapril, quercetin, suramin, estradiol, cycloheximide, tiazofurin, zafurin, AP23 573, rapamycin derivatives, non-immunosuppressive analogues of rapamycin (e.g., rapalog, AP21967, derivatives of rapalog), CCI-779 (an analogue of rapamcin available from Wyeth), sodium mycophenolic acid, benidipine hydrochloride, sirolimus, rapamune, metabolites, derivatives, and combinations thereof.